iNtRON Biotechnology, Inc.

KOSDAQ:A048530 Stock Report

Market Cap: ₩186.8b

iNtRON Biotechnology Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Alek Yoon

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure25yrs
CEO ownership15.0%
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business

Nov 15
iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business

We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt

May 03
We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt

We Believe iNtRON Biotechnology's (KOSDAQ:048530) Earnings Are A Poor Guide For Its Profitability

Mar 24
We Believe iNtRON Biotechnology's (KOSDAQ:048530) Earnings Are A Poor Guide For Its Profitability

Does iNtRON Biotechnology's (KOSDAQ:048530) Share Price Gain of 81% Match Its Business Performance?

Feb 28
Does iNtRON Biotechnology's (KOSDAQ:048530) Share Price Gain of 81% Match Its Business Performance?

iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) Stock Is Going Strong: Is the Market Following Fundamentals?

Jan 31
iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) Stock Is Going Strong: Is the Market Following Fundamentals?

iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet

Jan 05
iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet

What iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) 26% Share Price Gain Is Not Telling You

Dec 10
What iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) 26% Share Price Gain Is Not Telling You

iNtRON Biotechnology (KOSDAQ:048530) Share Prices Have Dropped 49% In The Last Five Years

Nov 26
iNtRON Biotechnology (KOSDAQ:048530) Share Prices Have Dropped 49% In The Last Five Years

CEO

Alek Yoon (55 yo)

25yrs

Tenure

Mr. Seong-Jun Yoon, also known as Alek, has been the Chief Executive Officer of iNtRON Biotechnology, Inc. since 2002 and serves as its President. Mr. Yoon served as the Chief Executive Officer of iNtRON B...

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 07:31
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

iNtRON Biotechnology, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sangsoo KimGoldman Sachs